Author

Deborah Young

University of AucklandORCID 0000-0003-1085-2824Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexandre MouravleviD· 2 shared Albert SnowballiD· 1 shared Andreas LiebiD· 1 shared Angela J. WuiD· 1 shared Barbara Fackelmeier· 1 shared Birger Victor DieriksiD· 1 shared Brigid RyaniD· 1 shared Connor A. ClemettiD· 1 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Alexandre MouravlevORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NeurosciencebioRxivPreprintMay 6, 2026

Systematic screening identifies elevated neurovascular BCL-XL in Parkinson's disease.

Kreesan Reddy, Eden Yin, Xi Hua Wu…·Birger Victor Dieriks

The paper identifies BCL-XL as a potential regulator of the neurovascular unit in Parkinson's disease through systematic screening of -Synuclein strain responses in pericytes.

DOI 10.64898/2026.05.03.722488

humanbulk RNA-seq

𝕏 PostBluesky

NeuroscienceExperimental NeurologyPeer-reviewedFeb 7, 2020

Astrocyte-selective AAV-ADAMTS4 gene therapy combined with hindlimb rehabilitation promotes functional recovery after spinal cord injury

Jarred M. Griffin, Barbara Fackelmeier, Connor A. Clemett…·Simon J. O’Carroll

This study combines AAV-ADAMTS4 gene therapy with hindlimb rehabilitation to enhance functional recovery after spinal cord injury by degrading CSPGs.

40 citations

mouseexperimental assay

𝕏 PostBluesky

NeuroscienceScience AdvancesPeer-reviewedApr 5, 2019

Olanzapine: a full and potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics

Mikail Weston, Teresa Kaserer, Angela J. Wu…·Andreas Lieb

The paper identifies olanzapine as a potent and full agonist for the hM4D(Gi) DREADD, enabling clinical translation of chemogenetics for CNS diseases.

61 citationstop 4%

humanexperimental assay

𝕏 PostBluesky